Mei-Sze Chua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3967288/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6662-6667.	7.1	1,255
2	Molecular Heterogeneity in Acute Renal Allograft Rejection Identified by DNA Microarray Profiling. New England Journal of Medicine, 2003, 349, 125-138.	27.0	673
3	A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature, 2017, 552, 57-62.	27.8	366
4	Antitumor Benzothiazoles. 14.1Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles. Journal of Medicinal Chemistry, 2001, 44, 1446-1455.	6.4	332
5	Antitumor Benzothiazoles. 8.1Synthesis, Metabolic Formation, and Biological Properties of theC- andN-Oxidation Products of Antitumor 2-(4-Aminophenyl)benzothiazolesâ^‡. Journal of Medicinal Chemistry, 1999, 42, 4172-4184.	6.4	225
6	5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Research, 2017, 27, 1231-1242.	12.0	200
7	Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nature Communications, 2017, 8, 16022.	12.8	151
8	Sprouty 2, an Inhibitor of Mitogen-Activated Protein Kinase Signaling, Is Down-Regulated in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 2048-2058.	0.9	146
9	An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene, 2005, 24, 3737-3747.	5.9	122
10	Antitumor Benzothiazoles. 7. Synthesis of 2-(4-Acylaminophenyl)benzothiazoles and Investigations into the Role of Acetylation in the Antitumor Activities of the Parent Amines. Journal of Medicinal Chemistry, 1999, 42, 381-392.	6.4	113
11	Small molecule antagonists of Tcf4/βâ€catenin complex inhibit the growth of HCC cells <i>in vitro</i> and <i>in vivo</i> . International Journal of Cancer, 2010, 126, 2426-2436.	5.1	113
12	Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Modern Pathology, 2007, 20, 76-83.	5.5	108
13	Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives. World Journal of Gastroenterology, 2014, 20, 333.	3.3	90
14	Harnessing big â€~omics' data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251.	17.8	90
15	Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Molecular Cancer, 2009, 8, 76.	19.2	87
16	SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Cell Death and Disease, 2019, 10, 612.	6.3	84
17	Suppression of Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up-Regulation of TGF-1²2. Neoplasia, 2011, 13, 735-IN25.	5.3	82
18	Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Molecular Cancer, 2011, 10, 16.	19.2	82

Mei-Sze Chua

#	Article	IF	CITATIONS
19	Sprouty and cancer: The first terms report. Cancer Letters, 2006, 242, 141-150.	7.2	81
20	Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells InÂVitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology, 2017, 152, 2022-2036.	1.3	81
21	Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget, 2015, 6, 25390-25401.	1.8	77
22	Comparative Profiling of Primary Colorectal Carcinomas and Liver Metastases Identifies LEF1 as a Prognostic Biomarker. PLoS ONE, 2011, 6, e16636.	2.5	56
23	<i>In vivo</i> MRSI of hyperpolarized [1â€ ¹³ C]pyruvate metabolism in rat hepatocellular carcinoma. NMR in Biomedicine, 2011, 24, 506-513.	2.8	54
24	N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Letters, 2008, 262, 133-142.	7.2	51
25	Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Research, 2006, 26, 1739-43.	1.1	47
26	Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget, 2014, 5, 5819-5831.	1.8	45
27	Suppressing N-Myc downstream regulated gene 1 reactivates senescence signaling and inhibits tumor growth in hepatocellular carcinoma. Carcinogenesis, 2014, 35, 915-922.	2.8	45
28	Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media and Molecular Imaging, 2012, 7, 363-372.	0.8	44
29	Molecular Profiling of Anemia in Acute Renal Allograft Rejection Using DNA Microarrays. American Journal of Transplantation, 2003, 3, 17-22.	4.7	42
30	An NIR-II/MR dual modal nanoprobe for liver cancer imaging. Nanoscale, 2020, 12, 11510-11517.	5.6	41
31	Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials, 2014, 35, 6964-6971.	11.4	39
32	Increased expression of cytotoxic effector molecules: Different interpretations for steroid-based and steroid-free immunosuppression. Pediatric Transplantation, 2003, 7, 53-58.	1.0	37
33	NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with CSK-3Î ² and Nur77 to prevent Î ² -catenin degradation. Oncotarget, 2015, 6, 29847-29859.	1.8	37
34	Antitumour Benzothiazoles. Part 15: The Synthesis and Physico-Chemical Properties of 2-(4-Aminophenyl)benzothiazole Sulfamate Salt Derivatives. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1093-1095.	2.2	32
35	Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling. Oncotarget, 2015, 6, 41722-41735.	1.8	26
36	Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Molecular Cancer, 2008, 7, 19.	19.2	25

Mei-Sze Chua

#	Article	IF	CITATIONS
37	An Automated, Quantitative, and Multiplexed Assay Suitable for Point-of-Care Hepatitis B Virus Diagnostics. Scientific Reports, 2019, 9, 15615.	3.3	24
38	Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes. BioMed Research International, 2013, 2013, 1-11.	1.9	21
39	Microarrays: new tools for transplantation research. Pediatric Nephrology, 2003, 18, 319-327.	1.7	20
40	Suppressing the <scp>CDC</scp> 37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth. Liver International, 2015, 35, 1403-1415.	3.9	19
41	Applications of microarrays to renal transplantation progress and possibilities. Frontiers in Bioscience - Landmark, 2003, 8, s913-923.	3.0	9
42	A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. Cancers, 2021, 13, 3977.	3.7	8
43	NIR-II imaging of hepatocellular carcinoma based on a humanized anti-GPC3 antibody. RSC Medicinal Chemistry, 2022, 13, 90-97.	3.9	8
44	Exploiting DNA Microarrays in Renal Transplantation. Graft: Organ and Cell Transplantation, 0, 5, 223-231.	0.0	2
45	Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology. Journal of Visualized Experiments, 2022, , .	0.3	2
46	<p>High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After RO Resection</p> . Cancer Management and Research, 2019, Volume 11, 10623-10632.	1.9	1